Back to search results

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Advanced Solid Tumor · Advanced Breast Cancer · Metastatic Breast Cancer · Hormone-receptor-positive Breast Cancer · Hormone Receptor Positive Breast Carcinoma · Hormone Receptor Positive Malignant Neoplasm of Breast · HER2-negative Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Non-small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado, United States

  • Florida Cancer Specialists and Research Institute, Lake Mary, Florida, United States

  • Karmanos Cancer Institute, Detroit, Michigan, United States

  • Washington University School of Medicine, St Louis, Missouri, United States

  • Duke Cancer Center, Durham, North Carolina, United States

  • James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

  • Scri Oncology Partners, Nashville, Tennessee, United States

  • The University of Texas Md Anderson Cancer Center, Houston, Texas, United States

  • Next Dallas, Irving, Texas, United States

  • Next Oncology, San Antonio, Texas, United States

  • Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia

  • Southern Highlands Private Hospital, Bowral, New South Wales, Australia

  • Concord Repatriation General Hospital, Concord, New South Wales, Australia

  • Macquarie University, North Ryde, New South Wales, Australia

  • Townsville University Hospital, Douglas, Queensland, Australia

  • Genesiscare St Andrews, Adelaide, South Australia, Australia

  • Austin Health, Heidelberg, Victoria, Australia

  • Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia

  • Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Brazil

  • Hospital Sirio Libanes Brasilia, Brasília, Brazil

  • Centro de Pesquisas Oncologicas Cepon, Florianópolis, Brazil

  • Liga Norte Riograndene Contra O Cancer, Natal, Brazil

  • Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petrópolis, Brazil

  • Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia, Porto Algre, Brazil

  • Instituto Nacional de Cancer, Rio de Janeiro, Brazil

  • Instituto Dor de Pesquisa E Ensino Hospital Sao Rafael, Salvador, Brazil

  • Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, São Paulo, Brazil

  • Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria, São Paulo, Brazil

  • Hospital Israelita Albert Einstein, São Paulo, Brazil

  • Beijing Cancer Hospital, Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital, Fuzhou, Fujian, China

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong, China

  • Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China

  • Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China

  • Fudan University Shanghai Cancer Centerpudong, Shanghai, Shanghai Municipality, China

  • Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, France

  • Centre Francois Baclesse, Caen, France

  • Centre Oscar Lambret, Lille, France

  • Institut Paoli Calmettes, Marseille, France

  • Institut Curie, Paris, France

  • Centre Eugene Marquis, Rennes, France

  • Institut de Cancerologie de Louest, Saint-Herblain, France

  • Institut Gustave Roussy, Villejuif, France

  • Nagoya University Hospital, Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East, Kashiwa, Chiba, Japan

  • Shizuoka Cancer Center, Suntogun, Shizuoka, Japan

  • Pulau Pinang Hospital, George Town, Malaysia

  • University Malaya Medical Centre, Kuala Lumpur, Malaysia

  • Sarawak General Hospital, Kuching, Malaysia

  • National Cancer Institute (Institut Kanser Negara), Putrajaya, Malaysia

  • The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Moldova

  • Harbour Cancer and Wellness, Auckland, New Zealand

  • Nzcr Christchurch, Christchurch, New Zealand

  • Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea

  • Gachon University Gil Medical Center, NamdongGu, Incheon Gwang'yeogsi, South Korea

  • Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, South Korea

  • The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu, Seoul Teugbyeolsi, South Korea

  • Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi, South Korea

  • Korea University Anam Hospital, SeongbukGu, Seoul Teugbyeolsi, South Korea

  • Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, South Korea

  • Asan Medical Center, SongpaGu, Seoul Teugbyeolsi, South Korea

  • Srinagarind Hospital (Khon Kaen University), Muang, Thailand

Study leads

  • Study Director

    BeOne Medicines

View source on ClinicalTrials.gov(opens in a new tab)